解析年龄、内分泌治疗持续性与激素受体阳性早期乳腺癌复发风险之间的关系:一项全国性队列研究
该研究利用法国国家健康数据系统,采用目标试验模拟方法,纳入121,601例激素受体阳性早期乳腺癌患者,评估持续内分泌治疗对5年无病生存率的影响。结果显示,34岁及以下患者严格持续治疗(允许≤30天中断)可使5年DFS从74.5%提高至78.8%,而允许≤90天和≤180天中断的获益分别降至1.3和1.0个百分点。50岁以上患者无论采用何种持续性定义,DFS获益均不超过1.9个百分点。
要点
- 34岁及以下患者严格持续内分泌治疗(≤30天中断)5年DFS提高4.3个百分点。
- 允许≤90天和≤180天中断的策略在年轻患者中DFS获益分别降至1.3和1.0个百分点。
- 50岁以上患者改善内分泌治疗持续性的DFS获益均不超过1.9个百分点。
核心结论
- 34岁及以下激素受体阳性早期乳腺癌女性严格持续内分泌治疗可获得的生存获益,凸显了为该人群制定改善内分泌治疗持续性的定制策略的必要性。
研究设计与样本
- 利用法国国家健康数据系统数据,采用目标试验模拟方法,纳入121,601例激素受体阳性早期乳腺癌患者,其中29.8%诊断时年龄小于50岁。
- 比较三种持续内分泌治疗策略(允许治疗中断不超过30、90或180连续天)与观察到的内分泌治疗持续性,估计5年无病生存获益。
主要发现
- 年轻患者较年长患者DFS更低且更可能停止内分泌治疗。
- 34岁及以下患者中,严格持续治疗(≤30天中断)使5年DFS比例从74.5%提高至78.8%(提高4.3个百分点,95%CI 2.6至7.2)。
- 34岁及以下患者中,允许≤90天和≤180天中断的策略使5年DFS获益分别降至1.3个百分点(95%CI 0.2至3.7)和1.0个百分点(95%CI -0.2至3.4)。
- 50岁以上患者中,无论采用何种持续性定义,改善内分泌治疗持续性的DFS获益均不超过1.9个百分点(与观察到的持续性相比)。
临床怎么用
- 原文结论指出,34岁及以下激素受体阳性早期乳腺癌女性严格持续内分泌治疗可获得的生存获益,凸显了为该人群制定改善内分泌治疗持续性的定制策略的必要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Young age is associated with increased risk of recurrence in hormone receptor (HR)-positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is a potential reason for the lower survival proportions observed in younger patients, but the survival benefits of improving adherence to ET in young patients remain unknown. MATERIALS AND METHODS: Using data from the French National Health Data System and target trial emulation methods, we considered three sustained ET persistence strategies (allowing treatment gaps of no more than 30, 90, or 180 continuous days) and estimated the 5-year disease-free survival (DFS) benefit of sustained ET persistence compared with observed ET persistence. RESULTS: A total of 121,601 patients with HR-positive eBC were included in the analyses, of whom 29.8% was younger than 50 years at diagnosis. Younger patients had lower DFS and were more likely to discontinue ET than older patients. In patients 34 years and younger, strict ET persistence (≤30-day gaps) improved 5-year DFS proportions from 74.5% to 78.8% (4.3 percentage points [95% CI, 2.6 to 7.2]) compared with observed persistence. ET persistence strategies allowing for ≤90-day and ≤180-day gaps reduced the 5-year DFS benefit in patients 34 years and younger to 1.3 (95% CI, 0.2 to 3.7) and 1.0 (95% CI, -0.2 to 3.4) percentage points, respectively. By contrast, DFS benefits of improved ET persistence in patients after 50 years old did not exceed 1.9 percentage points, compared with observed persistence, regardless of the persistence definition. CONCLUSION: The survival benefit that could be achieved with strict ET persistence in women 34 years and younger with HR-positive eBC highlights the need for tailored strategies to improve ET persistence in this population.
引用
- Dumas E, Jochum F, Coussy F, et al. Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor-Positive Early Breast Cancer: A Nationwide Cohort Study. J Clin Oncol. 2025. PMID: 40043224. doi:10.1200/JCO.24.01131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。